Search

Abstract Reactive oxygen species (ROS) produced in the mitochondria of skin cells play a significant role in the degradation of the extracellular matrix and induction of inflammatory responses, both of which are major contributors to skin aging. Antioxidants that reduce ROS production and inhibit inflammatory skin lesions are considered beneficial for the treatment of inflammatory skin diseases and prevention of skin aging. In this study, we evaluated the potential of Nypa fruticans (NF), which is known for its antioxidant properties, to mitigate tumor necrosis factor-alpha (TNF-α)- and interferon-gamma (IFN-γ)-induced damage in normal human epidermal keratinocytes. The major active constituents identified in NF include protocatechuic acid, hydroxybenzoic acid, procyanidin B, catechin, and epicatechin. NF significantly suppressed the production of ROS, nitric oxide (NO), and prostaglandin E2 (PGE2), while also reducing the levels of inflammatory cytokines interleukin-6 (IL-6) and interleukin-1 beta (IL-1β), which were elevated by TNF-α/IFN-γ stimulation. Furthermore, NF restored the expression of key skin barrier-related proteins such as serine peptidase inhibitor kazal type 5 (SPINK5), collagen type I alpha 1 chain (COLIA1), loricrin (LOR), aquaporin-3 (AQP3), and filaggrin (FLG). Additionally, NF significantly upregulated the expression of hyaluronan synthase (HAS) -1 and − 2 and human β-defensin (HBD) -2 and − 3, which are important for skin hydration and innate immune defense. These findings underscore the potential therapeutic applications of Nypa fruticans (NF) in mitigating oxidative stress, inflammation, skin barrier dysfunction, dehydration, and microbial imbalances. By targeting multiple pathways implicated in skin aging, NF represents a promising comprehensive approach for preserving skin health and addressing age-related dermatological conditions. Moreover, NF holds significant potential not only to alleviate the manifestations of skin aging but also to provide a basis for the development of innovative dermatological therapies. Future investigations should aim to further elucidate the clinical applications of NF in dermatology to maximize its therapeutic benefits.

Commensal bacteria interact with mucosal immune or epithelial cells to modulate the immune system. Probiotics have been proposed as a novel preventive or therapeutic method for immunological diseases because of their ability to alter intestinal microflora. Herein, lactobacilli isolated from kimchi were tested for their capacity to modulate intestinal allergy in mice. Lactic acid bacteria suppressed IL-4, IL-5, IL-13, and IL-17A cytokine production in splenocytes from OVA-sensitized mice in vitro. In a mouse model of food allergy, lactobacilli significantly inhibited the expression of Th2-associated gene products such as GATA3, IL-4, IL-5, IL-9, and IL-13 in the small intestine. Moreover, pro-inflammatory cytokine levels were lower in the lactobacillus group. Lactic acid bacteria also modulated mast cell infiltration and activation. Serum IgE/IgG2a and IgG1/IgG2a ratios were altered to alleviate Th2 responses. In conclusion, lactobacilli from kimchi effectively regulated intestinal allergy by suppressing Th2 responses and modulating mast cell function and recruitment.

Rice koji, used early in the manufacturing process for many fermented foods, produces diverse metabolites and enzymes during fermentation. Using gas chromatography time-of-flight mass spectrometry (GC-TOF-MS), ultrahigh-performance liquid chromatography linear trap quadrupole ion trap tandem mass spectrometry (UHPLC-LTQ-IT-MS/MS), and multivariate analysis we generated the metabolite profiles of rice koji produced by fermentation with Aspergillus oryzae (RK_AO) or Bacillus amyloliquefaciens (RK_BA) for different durations. Two principal components of the metabolomic data distinguished the rice koji samples according to their fermenter species and fermentation time. Several enzymes secreted by the fermenter species, including α-amylase, protease, and β-glucosidase, were assayed to identify differences in expression levels. This approach revealed that carbohydrate metabolism, serine-derived amino acids, and fatty acids were associated with rice koji fermentation by A. oryzae, whereas aromatic and branched chain amino acids, flavonoids, and lysophospholipids were more typical in rice koji fermentation by B. amyloliquefaciens. Antioxidant activity was significantly higher for RK_BA than for RK_AO, as were the abundances of flavonoids, including tricin, tricin glycosides, apigenin glycosides, and chrysoeriol glycosides. In summary, we have used MS-based metabolomics and enzyme activity assays to evaluate the effects of using different microbial species and fermentation times on the nutritional profile of rice koji.

Obesity associated with a Western diet such as a high-fat diet (HFD) is a known risk factor for inflammatory bowel disease (IBD) and colorectal cancer (CRC). In this study, we aimed to develop fecal microbiome data-based deep learning algorithms for the risk assessment of colorectal diseases. The effects of a HFD and a candidate food (Nypa fruticans, NF) on IBD and CRC risk reduction were also evaluated. Fecal microbiome data were obtained from 109 IBD patients, 111 CRC patients, and 395 healthy control (HC) subjects by 16S rDNA amplicon sequencing. IBD and CRC risk assessment prediction models were then constructed by deep learning algorithms. Dietary effects were evaluated based on fecal microbiome data from rats fed on a regular chow diet (RCD), HFD, and HFD plus ethanol extracts or water extracts of NF. There were significant differences in taxa when IBD and CRC were compared with HC. The diagnostic performance (area under curve, AUC) of the deep learning algorithm was 0.84 for IBD and 0.80 for CRC prediction. Based on the rat fecal microbiome data, IBD and CRC risks were increased in HFD-fed rats versus RCD-fed rats. Interestingly, in the HFD-induced obesity model, the IBD and CRC risk scores were significantly lowered by the administration of ethanol extracts of NF, but not by the administration of water extracts of NF. In conclusion, changes in the fecal microbiome of obesity by Western diet could be important risk factors for the development of IBD and CRC. The risk prediction model developed in this study could be used to evaluate dietary efficacy.

Various functional activities have been reported for the fermented soybean products doenjang (DJ) and cheonggukjang (CGJ), although no systemic investigations of their immune functions have been conducted to date. We examined the effects of an experimental diet of DJ, CGJ, or a mixture of unfermented raw material for 4 weeks on overall immunity and immune safety in mice. No significant alterations were observed in peripheral or splenic immune cells among groups. Enhanced splenic natural killer cell activity was observed in the DJ and CGJ groups compared with the plain diet group. T helper type-1 (Th1)-mediated immune responses were enhanced in the DJ and CGJ groups with an upregulated production ratio of IFN-γ vs. IL-4 and IgG2a vs. IgG1 in stimulated splenic T and B cells, respectively. Resistance to Listeria monocytogenes infection was observed in the DJ and CGJ groups. Overall, the results of this study suggest that DJ and CGJ intake consolidates humoral and cellular immunity to Th1 responses. [ABSTRACT FROM AUTHOR]

This study investigated the effects of combined grape pomace and omija fruit extracts (GO) on diabetes-related metabolic changes in type 2 diabetic db/db mice. The effects of GO were compared with those of a resveratrol and schizandrin mixture (RS), which is a mixture of major components of GO. Mice were fed a normal diet with RS (0.005% resveratrol and 0.02% schizandrin in diet, w/w) or GO (0.3% grape pomace ethanol extract and 0.05% omija fruit ethanol extract in diet, w/w) for seven weeks. RS and GO not only lowered the levels of blood and plasma glucose, HbA1c, insulin and homeostasis model assessment of insulin resistance (HOMA-IR) with a simultaneous decrease in hepatic gluconeogenic enzymes activities and adiposity, but also improved preservation of the pancreatic ß-cells. Plasma leptin and resistin levels were lower while the plasma adiponectin level was higher in the RS and GO groups than in the control group. Especially, GO increased hepatic glucokinase activity and gene expression and improved hepatic steatosis by elevating fatty acid oxidation compared to RS. These findings suggest that GO ameliorates hyperglycemia, adiposity and hepatic steatosis in type 2 diabetic mice. [ABSTRACT FROM AUTHOR]

To evaluate the pharmacokinetic and pharmacodynamic characteristics of YH1885, a novelproton pump inhibitor, a single-blind, randomized, placebo-controlled, dose-rising, parallel-group study was conducted in 46 healthy volunteers. The volunteers were randomly allocated to single dose groups of 60 mg, 100 mg, 150 mg, 200 mg, and 300 mg (6 subjects per dose, including 2 placebos) or to multiple-dose groups of 150 mg and 300 mg (once-daily dosing for 7 days; 8 subjects per dose, including 2 placebos). The multiple-dose study was conducted separately after the single-dose study. YH1885 was administered orally after overnight fasting. Serial blood samples, urine samples, and pharmacodynamic measurements were taken. Drug concentrations in plasma and urine were determined by liquid chromatography/mass spectrometry (LC/MS). Pharmacodynamic changes were evaluated by ambulatory intragastric pH monitoring and by serialmeas urements of serum gastrin concentrations. Assessments of safety and tolerability also were made. Plasma concentrations of YH1885 reached peak levels 1.3 to 2.5 hours after single-dose administration and then declined monoexponentially with a terminal half-life (t1/2) of 2.2 to 2.4 hours in dosage groups up to 200 mg in the single-dose study. YH1885 showed linear pharmacokinetic characteristics, and little accumulation occurred after multiple administrations. The parent drug was not detected in urine. Dose-related pharmacological effects were obvious for dose groups of 150 mg and higher in the single-dose study. The mean intragastric pH and the percentage of time at pH > 4were significantly increased. The onset of drug effect was rapid, and maximal effects were observed on the first day of administration during multiple dosing. Serum gastrin levels also showed rapid increases during dosing but with a weak doseeffect relationship. Neither serious nor dose-limiting adverse effects were observed. YH1885 was found to be safe and well tolerated and effectively inhibited acid secretion with dosedependent increases in intragastric pH. The acid-suppressing efficacy of YH1885 needs to be further evaluated in patients with gastric acid-related diseases. [ABSTRACT FROM AUTHOR]